Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Presents 2023 Financial Results and Provides 2024 Outlook
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria
Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology Congress
Newron Announces H1 2023 Results and Provides R&D Update
MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), presented substantial additional data from its study 014/015 at the 34th CINP World Congress of Neuropsychopharmacology from 7-10 May 2023 in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) from 11-15 May 2023 in Toronto, Ontario, Canada.
Newron Pharmaceuticals has reported substantial additional data from its study 014/015 of evenamide, as an add-on to an antipsychotic medication for the treatment of moderate-to-severe treatment-resistant schizophrenia (TRS).
Milan, Italy, May 3, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present six posters in various presentation formats at the upcoming 34th CINP World Congress of Neuropsychopharmacology, taking place 7-10 May 2023 at the Fairmont The Queen Elizabeth hotel in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) taking place 11-15 May 2023 at The Westin Harbour Castle in Toronto, Ontario, Canada.